Boehringer to build biopharma facility in China

Specifications:

Name:

Boehringer to build biopharma facility in China

Location:

China

Company:

Estimated Cost:

Source:

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. It has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a CGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology. The facility set up will include technical process development and cGMP manufacturing which will be ready for operations early 2016. Boehringer Ingelheim plans an investment of over 35 million EUR. The project will create up to 65 job opportunities with high qualification standards. Through the cooperation, both companies hope to bring here the know-how, technology and experience, all up to international standards. With a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, plus the government support, we plan to initiate the CMO manufacturing framework at this plant on a trial basis. This will provide an effective platform for middle and small-sized companies to industrialize their innovations. Thus, it will greatly prompt the development of China’s biopharmaceuticals manufacturing industry.” Hubertus von Baumbach, member of the Board of Managing Directors, in charge of Finance, commented: “Since 1994 Boehringer Ingelheim is present in China and has established significant research, development, manufacturing and marketing activities. With our investments in these innovation-driven areas we strive to meet the needs of our customers. The move to invest in biopharmaceuticals is in line with China’s overall growth plan for the next five years. Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing, will form the five pillars driving our business in China.” http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/06_june_2013_biopharmaceuticalsinchina.html Project Name Boehringer Ingelheim group to build biopharma facility in China Location China Commence 2013 Completion 2016 Estimated Investment EUR 35 million Capacity -NA- Key Players Boehringer Ingelheim group with Zhangjiang Biotech & Pharmaceutical Base Development Company